Letermovir

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cytomegalovirus Disease

Conditions

Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia

Trial Timeline

Jan 5, 2022 → Jan 14, 2025

NCT ID

NCT04904614

About Letermovir

Letermovir is a approved stage product being developed by Merck for Cytomegalovirus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04904614. Target conditions include Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection.

What happened to similar drugs?

6 of 20 similar drugs in Cytomegalovirus Disease were approved

Approved (6) Terminated (3) Active (11)

❌mRNA-1647ModernaPhase 3

🔄ASP0113 + PlaceboAstellas PharmaPhase 3

🔄Letermovir tablet + Letermovir IVMerckPhase 3

🔄Letermovir + PlaceboMerckPhase 3

🔄LetermovirMerckPhase 3

🔄Valganciclovir + GanciclovirRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07199465	Phase 1	Recruiting	Apr 24, 2026	May 19, 2028	Cytomegalovirus Prophylaxis
NCT06407232	Phase 3	Recruiting	Aug 8, 2024	Sep 1, 2026	Cytomegalovirus Infections
NCT05789615	Pre-clinical	Completed	Apr 1, 2023	Jan 10, 2025	CMV Infection
NCT05763823	Phase 3	Completed	Mar 24, 2023	Apr 18, 2024	Cytomegalovirus Infection
NCT04904614	Approved	Completed	Jan 5, 2022	Jan 14, 2025	Cytomegalovirus Disease
NCT04312841	Phase 2	Completed	Sep 15, 2020	Apr 9, 2024	B-Cell Prolymphocytic Leukemia
NCT03728426	Phase 2	Completed	Jan 11, 2019	Mar 28, 2022	Cytomegalovirus Infections

Competing Products

20 competing products in Cytomegalovirus Disease

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40
Letermovir	Merck	Phase 2	35